Lion Street Advisors’s Gilead Sciences GILD Stock Holding History

Lion Street Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-169	Closed	-$13K	–	164
2020 Q1	$13K	Buy	+169	New	+$11.7K	0.07%	132

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Lion Street Advisors's GILD Position: Q2 2020 in Review

Lion Street Advisors sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 169 shares — an estimated $13K sold.

Lion Street Advisors first reported a position in GILD in Q1 2020 and held it in 1 quarter. The position peaked at $13K in Q1 2020. 1,626 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

Lion Street Advisors reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
Lion Street Advisors sold 169 Gilead Sciences shares in Q2 2020, an estimated $13K.
Lion Street Advisors first reported a position in Gilead Sciences in Q1 2020 and held it in 1 quarter.
Lion Street Advisors's Gilead Sciences position peaked at $13K in Q1 2020.
1,626 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Lion Street Advisors's 13F filing for Q2 2020, filed 20 Jul 2020.